ABSTRACT
Upon infection, Trypanosoma cruzi triggers a strong immune response that has both protective and pathological consequences. In this work, several important questions regarding protective immunity are reviewed. Emphasis is placed on recent studies of the important protective role of CD8+ T cells and on previous studies of immunisation of domestic T. cruzi reservoirs that sought to address practical vaccination problems. Research on the maturation of memory cells and studies indicating that the prevalence of T. cruzi-specific T-cell responses and a high frequency of committed CD8+ T cells are associated with better clinical outcomes are also reviewed. Additionally, animal models in which protection was achieved without immunopathological consequences are discussed.
Subject(s)
Animals , Humans , Antibodies, Protozoan/immunology , /immunology , Chagas Disease/immunology , Protozoan Vaccines/immunology , /parasitology , Chagas Disease/parasitology , Chagas Disease/prevention & control , Disease Models, Animal , Immunity, CellularABSTRACT
A clinical-serological follow-up was carried out in a canine population in endemic foci of Leishmania braziliensis spread in northwestern Argentina. Each dog was studied in at least two visits, 309 + or - 15 days (X + or - SE) apart. Some initially healthy dogs (n=52) developed seroconversion or lesions. The clinical evolution of the disease in dogs resembles in many aspects the human disease. Similarities include the long duration of most ulcers with occasional healing or appearance of new ones and the late appearance of erosive snout lesions in some animals. Yearly incidence rates of 22.7 percent for seroconversion and of 13.5 percent for disease were calculated as indicators of the force of infection by this parasite upon the canine population